Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in MYGN — Myriad Genetics Inc

CIK 1423053 MIAMI, FL
Back to MYGN Full portfolio

Position in MYGN

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$2,038,688
+$361,147 QoQ
Shares Held
453,042
+66.1% QoQ
Ownership
0.480%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in MYGN Over Time

Shares Held

Position Value (USD)

Derivatives in MYGN

reported options exposure · as of Mar 31, 2026
CallValue
$93,150
CallShares
20,700
PutValue
$76,950
PutShares
17,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Diagnostics & Research

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $1,652,977,225 across 34 Diagnostics & Research names. MYGN ranks #22 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 TMO
Thermo Fisher Scientific Inc.
 864,489 $424,922,277
2 CRL
Charles River Laboratories International, Inc.
 1,212,152 $209,096,220
3 A
Agilent Technologies, Inc.
 1,801,714 $205,359,361
4 DHR
Danaher Corp /De/
 1,026,347 $194,595,390
5 MTD
Mettler Toledo International Inc/
 58,054 $73,217,704
6 GH
Guardant Health, Inc.
 775,941 $71,673,669
7 DGX
Quest Diagnostics Inc
 347,218 $68,047,783
8 IQV
Iqvia Holdings Inc.
 390,042 $66,517,762

All Filings in MYGN

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $76,950 17,100
2026-03-31 $2,038,688 453,042
2026-03-31 $93,150 20,700
2025-12-31 $1,677,541 272,771
2025-12-31 $107,010 17,400
2025-09-30 $135,924 18,800
2025-09-30 $4,136,643 572,150
2025-09-30 $432,354 59,800
2025-06-30 $75,402 14,200
2025-06-30 $132,219 24,900
2025-06-30 $9,085,521 1,711,021
2025-03-31 $136,598 15,400
2025-03-31 $4,746,611 535,131
2025-03-31 $161,434 18,200
2024-12-31 $10,491,453 765,241
2024-12-31 $283,797 20,700
2024-12-31 $212,505 15,500
2024-09-30 $884,697 32,300
2024-09-30 $1,864,190 68,061
2024-09-30 $495,759 18,100
2024-06-30 $533,228 21,800
2024-06-30 $43,148,662 1,764,050
2024-06-30 $362,008 14,800
2024-03-31 $304,876 14,300
2024-03-31 $29,134,781 1,366,547
2024-03-31 $550,056 25,800
2023-12-31 $543,576 28,400
2023-12-31 $453,618 23,700
2023-12-31 $22,280,529 1,164,082
2023-09-30 $208,520 13,000
2023-09-30 $10,798,833 673,244
2023-09-30 $742,652 46,300
2023-06-30 $875,577 37,773
2023-06-30 $208,620 9,000
2023-06-30 $375,516 16,200
2023-03-31 $69,690 3,000
2023-03-31 $49,828 2,145
2023-03-31 $1,739,927 74,900
2022-12-31 $976,523 67,300
2022-12-31 $481,688 33,197
2022-12-31 $40,628 2,800
2022-09-30 $518,976 27,200
2022-06-30 $423,361 23,300
2022-06-30 $755,872 41,600
2022-03-31 $786,240 31,200
2022-03-31 $1,207,080 47,900
2022-03-31 $1,084,154 43,022
2021-12-31 $1,838,160 66,600
2021-12-31 $811,440 29,400
2021-12-31 $1,485,541 53,824

Report a Problem

Category
Description
Email (optional, for follow-up)